GH Research (GHRS) Change in Cash (2020 - 2026)
GH Research (GHRS) posted quarterly Change in Cash of -$3.6 million for Q4 2025, down 132.87% year-over-year from $10.8 million in Q4 2024, and up 10.24% quarter-over-quarter from -$4.0 million in Q3 2025.
Analysis
GH Research (GHRS) Change in Cash (2020 - 2026) Analysis & Trends
GH Research's Change in Cash history runs 6 years deep, the most recent figure standing at -$3.6 million for Q4 2025.
- In Q4 2025, Change in Cash fell 132.87% year-over-year to -$3.6 million; the TTM figure through Dec 2025 stood at $142.3 million (up 531.03% YoY), while the FY2025 annual figure was $142.3 million, up 531.03% from the prior year.
- Change in Cash for Q4 2025 stood at -$3.6 million, up from -$4.0 million in the prior quarter.
- The five-year high for Change in Cash was $288.0 million in Q2 2021, with the low at -$91.5 million in Q4 2022.
- The 5-year median for Change in Cash is -$4.0 million (2021), against an average of $11.9 million.
- The sharpest annual moves came in 2021 and 2025: Change in Cash slumped 15309.09% in 2021, then soared 16496.25% in 2025.
- GH Research's Change in Cash stood at -$3.9 million in 2021, then sank by 2217.78% to -$91.5 million in 2022, then soared by 91.09% to -$8.2 million in 2023, then surged by 232.83% to $10.8 million in 2024, then sank by 132.87% to -$3.6 million in 2025.
- Business Quant data shows GHRS's Change in Cash at -$3.6 million in Q4 2025, -$4.0 million in Q3 2025, and $5.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | 103.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 103.19 Mn |
| Mar 31, 2026 | -2.03 Mn |
| Dec 31, 2025 | -3.56 Mn |
| Sep 30, 2025 | -3.96 Mn |
| Jun 30, 2025 | 5.67 Mn |
| Mar 31, 2025 | 144.12 Mn |
| Dec 31, 2024 | 10.83 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 9.68 Mn |
| Mar 31, 2024 | -879,000.00 |
| Dec 31, 2023 | -8.15 Mn |
| Sep 30, 2023 | -10.40 Mn |
| Jun 30, 2023 | -8.11 Mn |
| Mar 31, 2023 | -60.98 Mn |
| Dec 31, 2022 | -91.51 Mn |
| Sep 30, 2022 | -8.06 Mn |
| Jun 30, 2022 | -5.31 Mn |
| Mar 31, 2022 | -6.01 Mn |
| Dec 31, 2021 | -3.95 Mn |
| Sep 30, 2021 | -11.87 Mn |